AAD 2022 | Pfizer Información Médica

La información de esta página es seleccionada de materiales de congresos, áreas terapéuticas y de enfermedades. No pretende servir como una descripción general completa de todos los contenidos mencionados

Volver a Congresos

Presentación Oral

Erman Guler, Peter Anderson, Simran Marwaha, James Piercy, David Gruben, Andrey Lvov, Magdalena Trzeciak, Magdalena Czarnecka-Operacz Marzo 29, 2022 AAD 2022 Dermatitis Atópica

Atopic Dermatitis Treatment Patterns and Patient Burden in Russia and Poland

Ver Presentación

Presentación Oral

Raj Chovatiya, Maria Concetta Fargnoli, Brett King, Vivian Shi, Christian Vestergaard, Luis Puig, Pinaki Biswas, Marco DiBonaventura, Mark Levenberg, Claire Clibborn Marzo 29, 2022 AAD 2022 Dermatitis Atópica

Characteristics of the Efficacy Response Trajectory Among Patients Who Did Not Flare During the Maintenance Phase of JADE REGIMEN

Ver Presentación

Presentación Oral

Andrew F. Alexis, Zakiya P. Rice, Kenji Kabashima, Paula C. Luna, Jacob P. Thyssen, Magdalena Trzeciak, Pinaki Biswas, Gary L. Chan, Erman Guler, Mark Levenberg Marzo 29, 2022 AAD 2022 Dermatitis Atópica

Efficacy and Safety of Abrocitinib According to Geographies

Ver Presentación

Presentación Oral

Hordinsky M, Hebert A, Gooderham M, Kwon O, Murashkin N, Tran H, Wajsbrot D, Takiya L, Zwillich SH, Wolk R Marzo 29, 2022 AAD 2022 Alopecia Areata

Efficacy and safety of the oral JAK3/TEC inhibitor ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial

Ver Presentación

Presentación Oral

Mesinkovska N, Shapiro J, King B, Sinclair R, Zhang X, Lynde C, Gubelin Harcha W, Szepietowski JC, Wajsbrot D, Takiya L, Wolk R Marzo 29, 2022 AAD 2022 Alopecia Areata

Efficacy of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata over 48 weeks: results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial

Ver Presentación

Presentación Oral

Sinclair R, Mesinkovska N, Mitra D, Wajsbrot D, Wolk R, King B Marzo 29, 2022 AAD 2022 Alopecia Areata

Improvement in patient reported hair loss outcome measures in patients with alopecia areata treated with ritlecitinib: 48-week results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial

Ver Presentación

Presentación Oral

Amy Paller, Lawrence F. Eichenfield, Michael J Cork, Christine Bangert, Alan D. Irvine, Stephan Weidinger, Susan Johnson, Irina Lazariciu, Herwig Koppensteiner Marzo 29, 2022 AAD 2022 Dermatitis Atópica